Effects of Shielding Adenoviral Vectors with Polyethylene Glycol on Vector-Specific and Vaccine-Mediated Immune Responses
Abstract
Many individuals have been previously exposed to human adenovirus serotype 5 (Ad5). This prior immunity has long been known to hinder its use for gene therapy and as a gene-based vaccine. Given these immunogenicity problems, we have tested whether polyethylene glycol (PEG) can blunt immune effects against Ad5 during systemic and mucosal vaccination. Ad5 vectors were covalently modified with 5-, 20-, and 35-kDa linear PEG polymers and evaluated for their ability to produce immune responses against transgene antigen products and the vector itself. We show that shielding Ad5 with different-sized PEGs generally reduces transduction and primary antibody responses by the intramuscular or intranasal route. In contrast, PEGylated vectors generally appear better at boosting antibody responses in Ad-immune animals. Displaying either glucose or galactose on PEG mediated increased transduction and antibody responses by the intranasal, but not the intramuscular, route. In naive animals, PEGylated vectors generated T cell responses that were equal to or better than those by unmodified Ad. Priming by PEGylated vectors generally enabled better subsequent T cell responses after boost. Priming and boosting by PEGylated vectors produced T cell responses after boost that were equal to or higher than those produced by unmodified vectors. These data indicate that PEGylation can enable more effective application of Ad5 and perhaps other Ad serotype vaccines during prime–boost vaccination.
Get full access to this article
View all available purchase options and get full access to this article.
References
Andersson H.A.Barry M.A.2004. Maximizing antigen targeting to the proteasome for gene-based vaccinesMol. Ther.10432-446. Andersson, H.A., and Barry, M.A. (2004). Maximizing antigen targeting to the proteasome for gene-based vaccines. Mol. Ther. 10, 432–446.
Andersson H.A.Passeri M.F.Barry M.A.2005. Rad23 as a reciprocal agent for stimulating or repressing immune responsesHum. Gene Ther.16634-641. Andersson, H.A., Passeri, M.F., and Barry, M.A. (2005). Rad23 as a reciprocal agent for stimulating or repressing immune responses. Hum. Gene Ther. 16, 634–641.
Barouch D.H.Pau M.G.Custers J.H.Koudstaal W.Kostense S.Havenga M.J.Truitt D.M.Sumida S.M.Kishko M.G.Arthur J.C.Korioth-Schmitz B.Newberg M.H.Gorgone D.A.Lifton M.A.Panicali D.L.Nabel G.J.Letvin N.L.Goudsmit J.2004. Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunityJ. Immunol.1726290-6297. Barouch, D.H., Pau, M.G., Custers, J.H., Koudstaal, W., Kostense, S., Havenga, M.J., Truitt, D.M., Sumida, S.M., Kishko, M.G., Arthur, J.C., Korioth-Schmitz, B., Newberg, M.H., Gorgone, D.A., Lifton, M.A., Panicali, D.L., Nabel, G.J., Letvin, N.L., and Goudsmit, J. (2004). Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity. J. Immunol. 172, 6290–6297.
Crawford-Miksza L.Schnurr D.P.1996. Analysis of 15 adenovirus hexon proteins reveals the location and structure of seven hypervariable regions containing serotype-specific residuesJ. Virol.701836-1844. Crawford-Miksza, L., and Schnurr, D.P. (1996). Analysis of 15 adenovirus hexon proteins reveals the location and structure of seven hypervariable regions containing serotype-specific residues. J. Virol. 70, 1836–1844.
Croyle M.A.Chirmule N.Zhang Y.Wilson J.M.2001. “Stealth” adenoviruses blunt cell-mediated and humoral immune responses against the virus and allow for significant gene expression upon readministration in the lungJ. Virol.754792-4801. Croyle, M.A., Chirmule, N., Zhang, Y., and Wilson, J.M. (2001). “Stealth” adenoviruses blunt cell-mediated and humoral immune responses against the virus and allow for significant gene expression upon readministration in the lung. J. Virol. 75, 4792–4801.
Croyle M.A.Chirmule N.Zhang Y.Wilson J.M.2002. PEGylation of E1-deleted adenovirus vectors allows significant gene expression on readministration to liverHum. Gene Ther.131887-1900. Croyle, M.A., Chirmule, N., Zhang, Y., and Wilson, J.M. (2002). PEGylation of E1-deleted adenovirus vectors allows significant gene expression on readministration to liver. Hum. Gene Ther. 13, 1887–1900.
Croyle M.A.Le H.T.Linse K.D.Cerullo V.Toietta G.Beaudet A.Pastore L.2005. PEGylated helper-dependent adenoviral vectors: Highly efficient vectors with an enhanced safety profileGene Ther.12579-587. Croyle, M.A., Le, H.T., Linse, K.D., Cerullo, V., Toietta, G., Beaudet, A., and Pastore, L. (2005). PEGylated helper-dependent adenoviral vectors: Highly efficient vectors with an enhanced safety profile. Gene Ther. 12, 579–587.
Erbacher P.Bousser M.T.Raimond J.Monsigny M.Midoux P.Roche A.C.1996. Gene transfer by DNA/glycosylated polylysine complexes into human blood monocyte-derived macrophagesHum. Gene Ther.7721-729. Erbacher, P., Bousser, M.T., Raimond, J., Monsigny, M., Midoux, P., and Roche, A.C. (1996). Gene transfer by DNA/glycosylated polylysine complexes into human blood monocyte-derived macrophages. Hum. Gene Ther. 7, 721–729.
Fajac I.Briand P.Monsigny M.Midoux P.1999. Sugar-mediated uptake of glycosylated polylysines and gene transfer into normal and cystic fibrosis airway epithelial cellsHum. Gene Ther.10395-406. Fajac, I., Briand, P., Monsigny, M., and Midoux, P. (1999). Sugar-mediated uptake of glycosylated polylysines and gene transfer into normal and cystic fibrosis airway epithelial cells. Hum. Gene Ther. 10, 395–406.
Fields P.A.Kowalczyk D.W.Arruda V.R.Armstrong E.McCleland M.L.Hagstrom J.N.Pasi K.J.Ertl H.C.J.Herzog R.W.High K.A.2000. Role of vector in activation of T cell subsets in immune responses against the secreted transgene product factor IXMol. Ther.1225-235. Fields, P.A., Kowalczyk, D.W., Arruda, V.R., Armstrong, E., McCleland, M.L., Hagstrom, J.N., Pasi, K.J., Ertl, H.C.J., Herzog, R.W., and High, K.A. (2000). Role of vector in activation of T cell subsets in immune responses against the secreted transgene product factor IX. Mol. Ther. 1, 225–235.
Gomez-Roman V.R.Grimes G.J. Jr.Potti G.K.Peng B.Demberg T.Gravlin L.Treece J.Pal R.Lee E.M.Alvord W.G.Markham P.D.Robert-Guroff M.2006. Oral delivery of replication-competent adenovirus vectors is well tolerated by SIV- and SHIV-infected rhesus macaquesVaccine245064-5072. Gomez-Roman, V.R., Grimes, G.J., Jr., Potti, G.K., Peng, B., Demberg, T., Gravlin, L., Treece, J., Pal, R., Lee, E.M., Alvord, W.G., Markham, P.D., and Robert-Guroff, M. (2006). Oral delivery of replication-competent adenovirus vectors is well tolerated by SIV- and SHIV-infected rhesus macaques. Vaccine 24, 5064–5072.
Hofherr S.E.Mok S.Gushiken F.C.Lopez J.A.Barry M.A.2007. Polyethylene glycol modification of adenovirus reduces platelet activation, endothelial cell activation, and thrombocytopeniaHum. Gene Ther.18837-848. Hofherr, S.E., Mok, S., Gushiken, F.C., Lopez, J.A., and Barry, M.A. (2007). Polyethylene glycol modification of adenovirus reduces platelet activation, endothelial cell activation, and thrombocytopenia. Hum. Gene Ther. 18, 837–848.
Hofherr S.E.Shashkova E.V.Weaver E.A.Khare R.Barry M.A.2008. Modification of adenoviral vectors with polyethylene glycol modulates in vivo tissue tropism and gene expressionMol. Ther.161276-1282. Hofherr, S.E., Shashkova, E.V., Weaver, E.A., Khare, R., and Barry, M.A. (2008). Modification of adenoviral vectors with polyethylene glycol modulates in vivo tissue tropism and gene expression. Mol. Ther. 16, 1276–1282.
Lubeck M.D.Natuk R.Myagkikh M.Kalyan N.Aldrich K.Sinangil F.Alipanah S.Murthy S.C.Chanda P.K.Nigida S.M. Jr.Markham P.D.Zolla-Pazner S.Steimer K.Wade M.Reitz M.S. JR.Arthur L.O.Mizutani S.Davis A.Hung P.P.Gallo R.C.Eichberg J.Robert-Guroff M.1997. Long-term protection of chimpanzees against high-dose HIV-1 challenge induced by immunizationNat. Med.3651-658. Lubeck, M.D., Natuk, R., Myagkikh, M., Kalyan, N., Aldrich, K., Sinangil, F., Alipanah, S., Murthy, S.C., Chanda, P.K., Nigida, S.M., Jr., Markham, P.D., Zolla-Pazner, S., Steimer, K., Wade, M., Reitz, M.S., JR., Arthur, L.O., Mizutani, S., Davis, A., Hung, P.P., Gallo, R.C., Eichberg, J., and Robert-Guroff, M. (1997). Long-term protection of chimpanzees against high-dose HIV-1 challenge induced by immunization. Nat. Med. 3, 651–658.
Mok H.Palmer D.J.Ng P.Barry M.A.2005. Evaluation of polyethylene glycol modification of first-generation and helper-dependent adenoviral vectors to reduce innate immune responsesMol. Ther.1166-79. Mok, H., Palmer, D.J., Ng, P., and Barry, M.A. (2005). Evaluation of polyethylene glycol modification of first-generation and helper-dependent adenoviral vectors to reduce innate immune responses. Mol. Ther. 11, 66–79.
Ogawara K.Rots M.G.Kok R.J.Moorlag H.E.van Loenen A.M.Meijer D.K.Haisma H.J.Molema G.2004. A novel strategy to modify adenovirus tropism and enhance transgene delivery to activated vascular endothelial cells in vitro and in vivoHum. Gene Ther.15433-443. Ogawara, K., Rots, M.G., Kok, R.J., Moorlag, H.E., van Loenen, A.M., Meijer, D.K., Haisma, H.J., and Molema, G. (2004). A novel strategy to modify adenovirus tropism and enhance transgene delivery to activated vascular endothelial cells in vitro and in vivo. Hum. Gene Ther. 15, 433–443.
O'Riordan C.R.Lachapelle A.Delgado C.Parkes V.Wadsworth S.C.Smith A.E.Francis G.E.1999. PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivoHum. Gene Ther.101349-1358. O'Riordan, C.R., Lachapelle, A., Delgado, C., Parkes, V., Wadsworth, S.C., Smith, A.E., and Francis, G.E. (1999). PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo. Hum. Gene Ther. 10, 1349–1358.
Parrott M.B.Adams K.E.Mercier G.T.Mok H.Campos S.K.Barry M.A.2003. Metabolically biotinylated adenovirus for cell-targeting, ligand screening, and vector purificationMol. Ther.8689-702. Parrott, M.B., Adams, K.E., Mercier, G.T., Mok, H., Campos, S.K., and Barry, M.A. (2003). Metabolically biotinylated adenovirus for cell-targeting, ligand screening, and vector purification. Mol. Ther. 8, 689–702.
Roberts D.M.Nanda A.Havenga M.J.Abbink P.Lynch D.M.Ewald B.A.Liu J.Thorner A.R.Swanson P.E.Gorgone D.A.Lifton M.A.Lemckert A.A.Holterman L.Chen B.Dilraj A.Carville A.Mansfield K.G.Goudsmit J.Barouch D.H.2006. Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunityNature441239-243. Roberts, D.M., Nanda, A., Havenga, M.J., Abbink, P., Lynch, D.M., Ewald, B.A., Liu, J., Thorner, A.R., Swanson, P.E., Gorgone, D.A., Lifton, M.A., Lemckert, A.A., Holterman, L., Chen, B., Dilraj, A., Carville, A., Mansfield, K.G., Goudsmit, J., and Barouch, D.H. (2006). Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity. Nature 441, 239–243.
Schnell M.A.Zhang Y.Tazelaar J.Gao G.P.Yu Q.C.Qian R.Chen S.J.Varnavski A.N.Leclair C.Raper S.E.Wilson J.M.2001. Activation of innate immunity in nonhuman primates following intraportal administration of adenoviral vectorsMol. Ther.3708-722. Schnell, M.A., Zhang, Y., Tazelaar, J., Gao, G.P., Yu, Q.C., Qian, R., Chen, S.J., Varnavski, A.N., Leclair, C., Raper, S.E., and Wilson, J.M. (2001). Activation of innate immunity in nonhuman primates following intraportal administration of adenoviral vectors. Mol. Ther. 3, 708–722.
Sekaly R.P.2008. The failed HIV Merck vaccine study: A step back or a launching point for future vaccine development?J. Exp. Med.2057-12. Sekaly, R.P. (2008). The failed HIV Merck vaccine study: A step back or a launching point for future vaccine development? J. Exp. Med. 205, 7–12.
Sprangers M.C.Lakhai W.Koudstaal W.Verhoeven M.Koel B.F.Vogels R.Goudsmit J.Havenga M.J.Kostense S.2003. Quantifying adenovirus-neutralizing antibodies by luciferase transgene detection: Addressing preexisting immunity to vaccine and gene therapy vectorsJ. Clin. Microbiol.415046-5052. Sprangers, M.C., Lakhai, W., Koudstaal, W., Verhoeven, M., Koel, B.F., Vogels, R., Goudsmit, J., Havenga, M.J., and Kostense, S. (2003). Quantifying adenovirus-neutralizing antibodies by luciferase transgene detection: Addressing preexisting immunity to vaccine and gene therapy vectors. J. Clin. Microbiol. 41, 5046–5052.
Wortmann A.Vohringer S.Engler T.Corjon S.Schirmbeck R.Reimann J.Kochanek S.Kreppel F.2008. Fully detargeted polyethylene glycol-coated adenovirus vectors are potent genetic vaccines and escape from pre-existing anti-adenovirus antibodiesMol. Ther.16154-162. Wortmann, A., Vohringer, S., Engler, T., Corjon, S., Schirmbeck, R., Reimann, J., Kochanek, S., and Kreppel, F. (2008). Fully detargeted polyethylene glycol-coated adenovirus vectors are potent genetic vaccines and escape from pre-existing anti-adenovirus antibodies. Mol. Ther. 16, 154–162.
Xiang Z.Q.Pasquini S.Ertl H.C.1999. Induction of genital immunity by DNA priming and intranasal booster immunization with a replication-defective adenoviral recombinantJ. Immunol.1626716-6723. Xiang, Z.Q., Pasquini, S., and Ertl, H.C. (1999). Induction of genital immunity by DNA priming and intranasal booster immunization with a replication-defective adenoviral recombinant. J. Immunol. 162, 6716–6723.
Yang Y.Ertl H.C.J.Wilson J.M.1994. MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice injected with E1-deleted recombinant adenovirusesImmunity1433-442. Yang, Y., Ertl, H.C.J., and Wilson, J.M. (1994). MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice injected with E1-deleted recombinant adenoviruses. Immunity 1, 433–442.
Information & Authors
Information
Published In
Copyright
Copyright 2008, Mary Ann Liebert, Inc.
History
Published online: 4 December 2008
Published in print: December 2008
Accepted: 6 September 2008
Received: 20 July 2008
Authors
Author Disclosure Statement
E.W. and M.B. have no competing financial interests.
Metrics & Citations
Metrics
Citations
Export Citation
Export citation
Select the format you want to export the citations of this publication.
View Options
Get Access
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.⚠ Society Access
If you are a member of a society that has access to this content please log in via your society website and then return to this publication.